Cytokines and Chemokines in Mucosal Homeostasis

Inflammatory Bowel Disease: Translating basic science into clinical practice

Volumn , Issue , 2010, Pages 119-156

  Maillard, Michel H ^a,b   Snapper, Scott B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Anti inflammatory cytokines; Chemokines cytokines directing recruitment and migration of circulating leukocytes; Cytokines and chemokines in mucosal homeostasis; Pro inflammatory cytokines; Unclassified cytokines Interleukin 21, Interleukin 27, Interleukin 32

Indexed keywords

EID: 84885994368     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444318418.ch10     Document Type: Chapter

References (354)

1. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
2. Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001; 292: 1907-10.
3. Hans W, Scholmerich J, Gross V, Falk W. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw 2000; 11: 67-74.
4. Hornquist CE, Lu X, Rogers-FaniPMet al. G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol 1997; 158: 1068-77.
5. Ehrhardt RO, Ludviksson BR, Gray B, et al. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997; 158: 566-73.
6. Kontoyiannis D, Boulougouris G,ManoloukosMet al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumornecrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002; 196: 1563-74.
7. Spencer DM, Veldman GM, Banerjee S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002; 122: 94-105.
8. Kullberg MC, Ward JM, Gorelick PL, et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 1998; 66: 5157-66.
9. Simpson SJ, Shah S, ComiskeyMet al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998; 187: 1225-34.
10. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382: 171-4.
11. Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004; 202: 139-56.
12. Monteleone G, Biancone L, Marasco R, et al. Interleukin-12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112: 1169-78.
13. Mannon PJ, Fuss IJ,Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-79.
14. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patientswith moderate-to-severeCrohn's disease. Gastroenterology 2008; 135: 1130-41.
15. Arend WP, Palmer G, Gabay C. IL-1, IL-18 and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38.
16. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400-7.
17. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-74.
18. Yoshimoto T, Okamura H, Tagawa YI, et al. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997; 94: 3948-53.
19. Wirtz S, Becker C, Blumberg R, et al. Treatment of T celldependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 2002; 168: 411-20.
20. Kanai T, Watanabe M, Okazawa A, et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001; 121: 875-88.
21. Sivakumar PV, Westrich GM, Kanaly S, et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002; 50: 812-20.
22. Nakamura S, Otani T, Ijiri Y, et al. IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol 2000; 164: 3330-6.
23. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Cytokines and Chemokines in Mucosal Homeostasis 147 expression and localization in intestinal mucosal cells. J Immunol 1999; 162: 6829-35.
24. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163: 143-7.
25. Chen J, Liu X. The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. Cell Immunol 2009; 254: 85-90.
26. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-69.
27. Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res 2003; 23: 513-22.
28. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307: 430-3.
29. Nguyen DD, Maillard MH, Cotta-de-Almeida V, et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient inWiskott-Aldrich syndrome protein. Gastroenterology 2007; 133: 1188-97.
30. Mizoguchi A, Mizoguchi E, Chiba C, et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med 1996; 183: 847-56.
31. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998; 114: 385-91.
32. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994; 179: 589-600.
33. BergDJ, DavidsonN, KuhnRet al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98: 1010-20.
34. Uhlig HH, McKenzie BS,Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25: 309-18.
35. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-90.
36. Bregenholt S, Brimnes J, Nissen MH, Claesson MH. In vitro activated CD4+ T cells from interferon-gamma (IFN-gamma)- deficient mice induce intestinal inflammation in immunodeficient hosts. Clin Exp Immunol 1999; 118: 228-34.
37. MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-5.
38. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-70.
39. Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127-31.
40. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. J Gastroenterol 1995; 30 Suppl 8: 52-5.
41. Akagi S,Hiyama E, Imamura Y, Takesue Y, et al. Interleukin-10 expression in intestine of Crohn disease. Int J MolMed 2000; 5: 389-95.
42. Fais S, Capobianchi MR, SilvestriMet al. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994; 14: 235-8.
43. Murata Y, Ishiguro Y, Itoh J,, et al. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol 1995; 30 Suppl 8: 56-60.
44. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 Thelper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997; 150: 823-32.
45. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997; 113: 118-26.
46. Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985; 228: 149-54.
47. Kruglov AA, Kuchmiy A, Grivennikov SI, et al. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 2008; 19: 231-44.
48. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625-55.
49. Bruno ME, Kaetzel CS. Long-term exposure of the HT-29 human intestinal epithelial cell line to TNF causes sustained upregulation of the polymeric Ig receptor and proinflammatory genes through transcriptional and posttranscriptional mechanisms. J Immunol 2005; 174: 7278-84.
50. Loncar MB, Al-azzeh ED, Sommer PS, et al. Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide. Gut 2003; 52: 1297-303.
51. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-98.
52. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001; 107: 695-702.
53. Musch MW, Clarke LL, Mamah D, et al. T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest 2002; 110: 1739-47.
54. Mizoguchi E, Hachiya Y, Kawada M, et al. TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology 2008; 134: 470-80.
55. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
56. Dionne S, Hiscott J, D'Agata I, et al. Quantitative PCR analysis of TNFalpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997; 42: 1557-66.
57. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
58. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
59. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
60. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
61. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEngl J Med 2005; 353: 2462-76.
62. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33. quiz 591.
63. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
64. Schreiber S,Khaliq-KareemiM,Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
65. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
66. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57.
67. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti- TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
68. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26: 453-79.
69. Saddlack B, Merz H, Scholrle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
70. Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3: 521-30.
71. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995; 268: 1472-6.
72. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
73. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-41.
74. Fontenot JD, Rasmussen JP, GavinMA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-51.
75. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004; 172: 6519-23.
76. Malek TR, Yu A, Vincek V, et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002; 17: 167-78.
77. Autenrieth IB, Bucheler N, Bohn E, et al. Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation. Gut 1997; 41: 793-800.
78. MeijssenMA, Brandwein SL, Reinecker HC, et al. Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice. Am J Physiol 1998; 274: G472-9.
79. Simpson SJ, Mizoguchi E, Allen D, et al. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2- deficient colitis. Eur J Immunol 1995; 25: 2618-25.
80. Nagahama K, Ogawa A, Shirane K, et al. Protein kinase C theta plays a fundamental role in different types of chronic colitis. Gastroenterology 2008; 134: 459-69.
81. Schultz M, Tonkonogy SL, Sellon RK, et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999; 276: G1461-72.
82. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006; 25: 319-29.
83. Brynskov J, Tvede N, Andersen CB, Vilien M. Increased concentrations of interleukin 1 beta, interleukin-2 and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33: 55-8.
84. Mullin GE, Lazenby AJ, HarrisML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992; 102: 1620-7.
85. NiessnerM, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995; 101: 428-35.
86. Gurbindo C, Sabbah S, Menezes J, et al. Interleukin-2 production in pediatric inflammatory bowel disease: evidence for dissimilar mononuclear cell function in Crohn's disease and ulcerative colitis. J Pediatr Gastroenterol Nutr 1993; 17: 247-54.
87. Shinoda M, Haruta J, Tanimoto M, et al. Lamina propria mononuclear cells express and respond to interleukin-2 differently in Crohn's disease and ulcerative colitis. Intern Med 1996; 35: 679-85.
88. Sparano JA, Brandt LJ, Dutcher JP, et al. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2. Ann Intern Med 1993; 118: 617-8.
89. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti- CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 65-75.
90. Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further Cytokines and Chemokines in Mucosal Homeostasis 149 experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 23: 1435-42.
91. Van Assche G, Sandborn WJ, Feagan BG,, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006; 55: 1568-74.
92. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9.
93. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004; 117: 561-74.
94. Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998; 352: 1742-6.
95. Cominelli F, Nast CC, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972-80.
96. Mizoguchi E, Mizoguchi A, Bhan AK. Role of cytokines in the early stages of chronic colitis in TCR alpha-mutant mice. Lab Invest 1997; 76: 385-97.
97. Kwon KH, Murakami A, Hayashi R, Ohigashi H. Interleukin- 1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 2005; 337: 647-54.
98. Arai Y, Takanashi H, Kitagawa H, Okayasu I. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998; 10: 890-6.
99. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta - converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001; 98: 13249-54.
100. Bauer C, Loher F, DauerMet al. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6mice and suppresses IP-10 mRNA but not TNFalpha mRNA expression. Dig Dis Sci 2007; 52: 1642-52.
101. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456: 264-8.
102. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005; 307: 734-8.
103. Casini-Raggi V, Kam L, Chong YJ, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434-40.
104. LudwiczekO, Vannier E, Borggraefe I, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004; 138: 323-9.
105. Reimund JM,Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis andCrohn'sdisease. JClin Immunol 1996; 16: 144-50.
106. Youngman KR, Simon PL, West GA, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993; 104: 749-58.
107. McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998; 42: 214-9.
108. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992; 33: 773-8.
109. Hyams JS, Fitzgerald JE,WyzgaNet al. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci 1994; 39: 1893-9.
110. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-61.
111. Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J Clin Rheumatol 2003; 9: 276-7.
112. Mitsuyama K, Sata M, Rose-John S. Interleukin-6 transsignaling in inflammatory bowel disease. Cytokine Growth Factor Rev 2006; 17: 451-61.
113. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
114. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-4.
115. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-9.
116. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-68.
117. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 315-25.
118. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-20.
119. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol 1997; 158: 5791-6.
120. Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471-81.
121. Yamamoto M, Yoshizaki K, Kishimoto T, ItoH. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878-82.
122. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8.
123. Mizoguchi E, Mizoguchi A, Takedatsu H,, et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002; 122: 134-44.
124. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10: 39-49.
125. Alonzi T, Newton IP, Bryce PJ, et al. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 2004; 26: 45-56.
126. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-52.
127. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factoralpha, interleukin-1 beta and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
128. Mitsuyama K, Sasaki E, Toyonaga A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991; 50: 104-11.
129. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32: 1531-4.
130. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-9.
131. Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156-64.
132. Mitsuyama K, Tomiyasu N, Suzuki A, et al. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 2006; 143: 125-31.
133. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-96. discussion 947.
134. Migone TS, Zhang J, Luo X, et al. TL1A is a TNFlike ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479-92.
135. Bamias G, Mishina M, Nyce M, et al. Role of TL1A and its receptor DR3 in twomodels of chronic murine ileitis. Proc Natl Acad Sci USA 2006; 103: 8441-6.
136. Prehn JL, Thomas LS, Landers CJ, et al. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 2007; 178: 4033-8.
137. Papadakis KA, Prehn JL, Landers C, et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 2004; 172: 7002-7.
138. Papadakis KA, Zhu D, Prehn JL, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 2005; 174: 4985-90.
139. Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008; 135: 552-67.
140. Brewer S, McPherson M, Fujiwara D, et al. Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro- D-glucose and positron emission tomography. Gastroenterology 2008; 135: 744-55.
141. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003; 171: 4868-74.
142. Prehn JL, Mehdizadeh S, Landers CJ, et al. Potential role for TL1A, the new TNFfamily member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol 2004; 112: 66-77.
143. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-25.
144. Aggarwal S, Ghilardi N, XieMHet al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-4.
145. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17- producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-32.
146. Veldhoen M, HockingRJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-89.
147. McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009; 10: 314-24.
148. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-42.
149. Wiekowski MT, Leach MW, Evans EW, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility and premature death. J Immunol 2001; 166: 7563-70.
150. Becker C,Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003; 112: 693-706.
151. Happel KI, Dubin PJ, Zheng M, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 2005; 202: 761-9.
152. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-83.
153. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-6.
154. Elson CO, Cong Y, Weaver CT, et al. Monoclonal antiinterleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132: 2359-70.
155. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are downregulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006; 12: 9-15.
156. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3.
157. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-66.
158. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-33.
159. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004; 110: 55-62.
160. Kinugasa T, Sakaguchi T, Gu X, Reinecker HC. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 2000; 118: 1001-11.
161. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849-61.
162. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
163. Nielsen OH, Kirman I, Rudiger N, et al. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 180-5.
164. Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008; 14: 437-45.
165. Coffman RL. Origins of the T(H)1-T(H)2 model: a personal perspective. Nat Immunol 2006; 7: 539-41.
166. Zhu J, Paul WE. CD4 T cells: fates, functions and faults. Blood 2008; 112: 1557-69.
167. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313-9.
168. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-96.
169. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998; 188: 1929-39.
170. Mizoguchi A, Mizoguchi E, Bhan AK. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice. Gastroenterology 1999; 116: 320-6.
171. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111: e622-7.
172. Dohi T, Fujihashi K, Rennert PD, et al. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J Exp Med 1999; 189: 1169-80.
173. Nielsen OH, Koppen T, Rudiger N, et al. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci 1996; 41: 1786-93.
174. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-7.
175. Takedatsu H, Mitsuyama K, Matsumoto S, et al. Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur J Immunol 2004; 34: 1561-9.
176. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008; 1: pe55.
177. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK T cells. Immunity 2002; 17: 629-38.
178. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGFbeta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007; 178: 5859-70.
179. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5 and IL-13 and Th2-associated pathologies in vivo. Immunity 2001; 15: 985-95.
180. Fallon PG, Ballantyne SJ, Mangan NE, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5 and IL-13 at the onset of helminth expulsion. J Exp Med 2006; 203: 1105-16.
181. Owyang AM, Zaph C, Wilson EH, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 2006; 203: 843-9.
182. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
183. Davidson NJ, Leach MW, Fort MM, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996; 184: 241-51.
184. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-42.
185. Powrie F, LeachMW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1: 553-62.
186. Hagenbaugh A, Sharma S, Dubinett SMet al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997; 185: 2101-10.
187. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004.
188. Dieleman LA, Elson CO, Tennyson GS, Beagley KW. Kinetics of cytokine expression during healing of acute colitis in mice. Am J Physiol 1996; 271: G130-6.
189. Kanai T, Kawamura T, Dohi T, et al. TH1/TH2-mediated colitis induced by adoptive transfer of CD4+CD45RBhigh T lymphocytes into nude mice. Inflamm Bowel Dis 2006; 12: 89-99.
190. Kamanaka M, Kim ST,Wan YY, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 2006; 25: 941-52.
191. Maynard CL, Harrington LE, Janowski KM, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol 2007; 8: 931-41.
192. Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-30.
193. Lindsay J,Van MontfransC, Brennan F, et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 2002; 9: 1715-21.
194. Steidler L, HansW, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-5.
195. Melgar S, Yeung MM, Bas A, et al. Over-expression of interleukin in mucosal T 2 cells of patients with active ulcerative colitis. Clin Exp Immunol 2003; 134: 127-37.
196. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 754-9.
197. Wahl SM. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007; 19: 55-62.
198. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factorbeta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
199. Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol 1993; 264: G179-86.
200. Kim PH, Kagnoff MF. Transforming growth factor beta 1 increases IgA isotype switching at the clonal level. J Immunol 1990; 145: 3773-8.
201. Miller A, Lider O, Roberts AB, et al. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89: 421-5.
202. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-40.
203. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002; 195: 1499-505.
204. Ludviksson BR, Ehrhardt RO, Strober W. TGFbeta production regulates the development of the 2,4,6-trinitrophenolconjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997; 159: 3622-8.
205. Nakamura K, Kitani A, Fuss I, et al. TGFbeta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004; 172: 834-42.
206. Powrie F, Carlino J, Leach MW, et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996; 183: 2669-74.
207. Piccirillo CA, Letterio JJ, Thornton AM, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 2002; 196: 237-46.
208. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J Exp Med 2005; 202: 901-6.
209. Fahlen L, Read S, Gorelik L, et al. T cells that cannot respond to TGFbeta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 2005; 201: 737-46.
210. Coombes JL, Siddiqui KR, Arancibia-CarcamoCV, et al. Afunctionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGFbeta and retinoic acid-dependent mechanism. J Exp Med 2007; 204: 1757-64.
211. Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007; 204: 1775-85.
212. IwataM, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527-38.
213. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-transretinoic acid mediates enhanced T reg cell growth, differentiation and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204: 1765-74.
214. Mucida D, Park Y, KimGet al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 256-60.
215. BabyatskyMW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975-84.
216. di Mola FF, Friess H, Scheuren A, et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999; 229: 67-75.
217. Del Zotto B, Mumolo G, PronioAMet al. TGFbeta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol 2003; 134: 120-6.
218. Xian CJ, Xu X, Mardell CE, et al. Site-specific changes in transforming growth factor-alpha and -beta1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 591-600.
219. Ohtani H, Kagaya H, Nagura H. Immunohistochemical localization of transforming growth factor-beta receptors I and II in inflammatory bowel disease. J Gastroenterol 1995; 30 Suppl 8: 76-7.
220. Burke JP, Ferrante M, Dejaegher K, et al. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis 2008; 14: 1197-204.
221. Fichtner-Feigl S, StroberW, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGFbeta1 production and fibrosis. Nat Med 2006; 12: 99-106.
222. Vallance BA, Gunawan MI, Hewlett B, et al. TGFbeta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005; 289: G116-28.
223. Monteleone G, Kumberova A, CroftNMet al. Blocking Smad7 restores TGFbeta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-9.
224. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
225. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168: 5397-402.
226. Wolk K, Kunz S,Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241-54.
227. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17: 367-80.
228. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129: 969-84.
229. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-44.
230. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-57.
231. Radaeva S, Sun R, Pan HN, et al. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39: 1332-42.
232. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate Cytokines and Chemokines in Mucosal Homeostasis 153 with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008; 14: 204-12.
233. Goldman SJ. Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995; 13: 462-71.
234. Leng SX, Elias JA. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol 1997; 159: 2161-8.
235. Schwertschlag US, Trepicchio WL, Dykstra KH, et al. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999; 13: 1307-15.
236. Bozza M, Bliss JL, Maylor R, et al. Interleukin-11 reduces T-celldependent experimental liver injury in mice. Hepatology 1999; 30: 1441-7.
237. Deutscher N, Bataille F, Hausmann M, et al. Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. Int J Colorectal Dis 2006; 21: 573-81.
238. Peterson RL, Bozza MM, Dorner AJ. Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation.AmJ Pathol 1996; 149: 895-902.
239. Qiu BS, Pfeiffer CJ, Keith JC Jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996; 41: 1625-30.
240. Greenwood-Van Meerveld B, Tyler K, Keith JC Jr. Recombinant human interleukin-11 modulates ion transport and mucosal inflammation in the small intestine and colon. Lab Invest 2000; 80: 1269-80.
241. Peterson RL, Wang L, Albert L, et al. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 1998; 78: 1503-12.
242. Trepicchio WL, OzawaM,Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-37.
243. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16: 399-406.
244. Herrlinger KR,Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006; 101: 793-7.
245. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-9.
246. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1419-23.
247. Fina D, Sarra M, FantiniMC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134: 1038-48.
248. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005; 128: 687-94.
249. Hunter CA,Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev 2004; 202: 106-14.
250. Batten M, Li J, Yi S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7: 929-36.
251. Nieuwenhuis EE, Neurath MF, Corazza N, et al. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad SciUSA 2002; 99: 16951-6.
252. Villarino AV, Artis D, Bezbradica JS, et al. IL-27R deficiency delays the onset of colitis and protects fromhelminth-induced pathology in a model of chronic IBD. Int Immunol 2008; 20: 739-52.
253. Honda K, Nakamura K, Matsui N, et al. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm Bowel Dis 2005; 11: 1044-52.
254. Kim SH, Han SY, Azam T, et al. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005; 22: 131-42.
255. Nishimoto KP, Laust AK, Nelson EL. A human dendritic cell subset receptive to the Venezuelan equine encephalitis virusderived replicon particle constitutively expresses IL-32. J Immunol 2008; 181: 4010-8.
256. Shioya M, Nishida A, Yagi Y, et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007; 149: 480-6.
257. Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1- dependent mechanism. Proc Natl Acad Sci USA 2005; 102: 16309-14.
258. ShodaH, Fujio K,YamaguchiYet al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006; 8: R166.
259. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-44.
260. Rasmussen SJ, Eckmann L, Quayle AJ, et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997; 99: 77-87.
261. Sainathan SK, Hanna EM, Gong Q, et al. Granulocyte macrophage colony-stimulating factor ameliorates DSSinduced experimental colitis. Inflamm BowelDis 2008; 14: 88-99.
262. Xu Y, Hunt NH, Bao S. The role of granulocyte macrophagecolony- stimulating factor in acute intestinal inflammation. Cell Res 2008; 18: 1220-9.
263. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360: 1478-80.
264. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352: 2193-201.
265. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005; 21: 391-400.
266. Noguchi M, Hiwatashi N, Liu ZX, Toyota T. Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion 2001; 63 Suppl 1: 32-6.
267. Agnholt J, Kelsen J, Brandsborg B, et al. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease -a possible target for infliximab treatment. Eur J Gastroenterol Hepatol 2004; 16: 649-55.
268. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174: 6571-6.
269. Porter BO, Malek TR. Thymic and intestinal intraepithelial T lymphocyte development are each regulated by the gammacdependent cytokines IL-2, IL-7 and IL-15. Semin Immunol 2000; 12: 465-74.
270. Laky K, Lefrancois L, Lingenheld EG, et al. Enterocyte expression of interleukin 7 induces development of gammadelta T cells and Peyer's patches. J Exp Med 2000; 191: 1569-80.
271. Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998; 187: 389-402.
272. von Freeden-Jeffry U, Davidson N,Wiler R, et al. IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis. J Immunol 1998; 161: 5673-80.
273. Totsuka T, Kanai T, Nemoto Y, et al. IL-7 Is essential for the development and the persistence of chronic colitis. J Immunol 2007; 178: 4737-48.
274. Okada E, YamazakiM, TanabeMet al. IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4+ mucosal T cells in mice. Am J Physiol Gastrointest Liver Physiol 2005; 288: G745-54.
275. Yamazaki M, Yajima T, Tanabe M, et al. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol 2003; 171: 1556-63.
276. Tomita T, Kanai T, Nemoto Y, et al. Systemic, but not intestinal, IL-7 is essential for the persistence of chronic colitis. J Immunol 2008; 180: 383-90.
277. Yamamoto S, Shimizu S, Kiyonaka S, et al. TRPM2-mediated Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. NatMed 2008; 14: 738-47.
278. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
279. Scheerens H, Hessel E, de Waal-Malefyt R, et al. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/-mice and Rag- 2-/-mice reconstituted with CD4+CD45RBhigh T cells. Eur J Immunol 2001; 31: 1465-74.
280. Yang SK, Choi MS, Kim OH, et al. The increased expression of an array of C-X-C and C-C chemokines in the colonic mucosa of patientswith ulcerative colitis: regulation by corticosteroids. Am J Gastroenterol 2002; 97: 126-32.
281. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-21.
282. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions and antagonism. Annu Rev Immunol 2007; 25: 787-820.
283. Kucharzik T, Lugering N, Pauels HG, et al. IL-4, IL-10 and IL-13 down-regulatemonocyte-chemoattracting protein-1 (MCP- 1) production in activated intestinal epithelial cells. Clin Exp Immunol 1998; 111: 152-7.
284. Warhurst AC, Hopkins SJ, Warhurst G. Interferon gamma induces differential upregulation of alpha and beta chemokine secretion in colonic epithelial cell lines. Gut 1998; 42: 208-13.
285. Motomura Y, Khan WI, El-Sharkawy RT, et al. Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. Gut 2006; 55: 662-70.
286. Khan WI, Motomura Y, Wang H, et al. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol 2006; 291: G803-11.
287. Andres PG, Beck PL, Mizoguchi E, et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000; 164: 6303-12.
288. Tokuyama H, Ueha S, KurachiMet al. The simultaneous blockade of chemokine receptors CCR2, CCR5 andCXCR3 by a nonpeptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol 2005; 17: 1023-34.
289. Reinecker HC, Loh EY, Ringler DJ, et al. Monocytechemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995; 108: 40-50.
290. Mazzucchelli L, Hauser C, Zgraggen K, et al. Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol 1996; 178: 201-6.
291. Grimm MC, Elsbury SK, Pavli P, Doe WF. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J Leukoc Biol 1996; 59: 804-12.
292. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis andCrohn's disease. J Pathol 2003; 199: 28-35.
293. McCormack G, Moriarty D, O'Donoghue DP, et al. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001; 50: 491-5.
294. Connor SJ, Paraskevopoulos N, Newman R, et al. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 2004; 53: 1287-94.
295. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
296. Ajuebor MN, Kunkel SL, Hogaboam CM. The role of CCL3/macrophage inflammatory protein-1alpha in experimental colitis. Eur J Pharmacol 2004; 497: 343-9.
297. Pender SL, Chance V, Whiting CV, et al. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model. Gut 2005; 54: 1114-20.
298. AjueborMN, Hogaboam CM, Kunkel SL, et al. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 2001; 166: 552-8.
299. Masunaga Y, Noto T, Suzuki K, et al. Expression profiles of cytokines and chemokines in murine MDR1a-/-colitis. Inflamm Res 2007; 56: 439-46.
300. Ansari N, Abdulla J, Zayyani N, et al. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? J Clin Pathol 2006; 59: 1066-72.
301. Uguccioni M, Gionchetti P, Robbiani DF, et al. Increased expression of IP-10, IL-8,MCP-1 andMCP-3 in ulcerative colitis. Am J Pathol 1999; 155: 331-6.
302. Oki M, Ohtani H, Kinouchi Y, et al. Accumulation of CCR5+ T cells around RANTES+ granulomas in Crohn's disease: a pivotal site of Th1-shifted immune response? Lab Invest 2005; 85: 137-45.
303. Izadpanah A, Dwinell MB, Eckmann L, et al. Regulated MIP- 3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am J Physiol Gastrointest Liver Physiol 2001; 280: G710-9.
304. Kwon JH, Keates S, Bassani L, et al. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP- 3alpha) production in normal colon and inflammatory bowel disease. Gut 2002; 51: 818-26.
305. Varona R, Cadenas V, Flores J, et al. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol 2003; 33: 2937-46.
306. Katchar K, Kelly CP, Keates S, et al. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice. AmJ Physiol Gastrointest Liver Physiol 2007; 292: G1263-71.
307. Wen H, Hogaboam CM, Lukacs NW, et al. The chemokine receptor CCR6 is an important component of the innate immune response. Eur J Immunol 2007; 37: 2487-98.
308. Teramoto K, Miura S, Tsuzuki Y, et al. Increased lymphocyte trafficking to colonicmicrovessels is dependent onMAdCAM- 1 and C-C chemokine mLARC/CCL20 in DSS-induced mice colitis. Clin Exp Immunol 2005; 139: 421-8.
309. Salazar-Gonzalez RM, Niess JH, Zammit DJ, et al. CCR6- mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches. Immunity 2006; 24: 623-32.
310. Wang C, Kang SG, Lee J, et al. The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol 2009; 2 (2):173-83.
311. Wurbel MA, Philippe JM, Nguyen C, et al. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol 2000; 30: 262-71.
312. Pabst O, Ohl L, Wendland M, et al. Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med 2004; 199: 411-6.
313. SvenssonM,Marsal J, Ericsson A, et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest 2002; 110: 1113-21.
314. Marsal J, Svensson M, Ericsson A, et al. Involvement of CCL25 (TECK) in the generation of the murine small-intestinal CD8alpha alpha+CD3+ intraepithelial lymphocyte compartment. Eur J Immunol 2002; 32: 3488-97.
315. Johansson-Lindbom B, Svensson M, Wurbel MA, et al. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198: 963-9.
316. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424: 88-93.
317. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005; 202: 1063-73.
318. Worbs T, Bode U, Yan S, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med 2006; 203: 519-27.
319. Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051-61.
320. Papadakis KA, Prehn J, Moreno ST, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel fromcolonic Crohn's disease. Gastroenterology 2001; 121: 246-54.
321. Saruta M, Yu QT, Avanesyan A, et al. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol 2007; 178: 3293-300.
322. Schnyder-Candrian S, Walz A. Neutrophil-activating protein ENA-78 and IL-8 exhibit different patterns of expression in lipopolysaccharide- and cytokine-stimulated human monocytes. J Immunol 1997; 158: 3888-94.
323. Keates S, Keates AC, Mizoguchi E, et al. Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol 1997; 273: G75-82.
324. Z'Graggen K, Walz A, Mazzucchelli L, et al. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 1997; 113: 808-16.
325. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045-9.
326. Li J, Moran T, Swanson E, et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004; 13: 1715-25.
327. Mazzucchelli L, Hauser C, Zgraggen K, et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol 1994; 144: 997-1007.
328. Mitsuyama K, Toyonaga A, Sasaki E, et al. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994; 96: 432-6.
329. Daig R, Andus T,Aschenbrenner E, et al. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996; 38: 216-22.
330. Nielsen OH, Rudiger N, Gaustadnes M, Horn T. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand J Gastroenterol 1997; 32: 1028-34.
331. Izzo RS,Witkon K, Chen AI, et al. Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 1447-52.
332. Raab Y, Gerdin B, Ahlstedt S, Hallgren R. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 1993; 34: 1203-6.
333. Gijsbers K, Van Assche G, Joossens S, et al. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol 2004; 34: 1992-2000.
334. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-8.
335. MaQ, JonesD, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficientmice. Proc Natl Acad Sci USA 1998; 95: 9448-53.
336. Mikami S, Nakase H, Yamamoto S, et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 2008; 327: 383-92.
337. Muehlhoefer A, Saubermann LJ, Gu X, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000; 164: 3368-76.
338. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-8.
339. Lucas AD, Chadwick N, Warren BF, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001; 158: 855-66.
340. Sans M, Danese S, de la Motte C, et al. Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology 2007; 132: 139-53.
341. Singh JC, Cruickshank SM, Newton DJ, et al. Toll-like receptormediated responses of primary intestinal epithelial cells during the development of colitis. Am J Physiol Gastrointest Liver Physiol 2005; 288: G514-24.
342. Cornet A, Savidge TC, Cabarrocas J, et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci USA 2001; 98: 13306-11.
343. Shaikh RB, Santee S, Granger SWet al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation and tissue destruction. J Immunol 2001; 167: 6330-7.
344. Wirtz S, Finotto S, Kanzler S, et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF plus IFN-gammaproducing CD4+ T cells that respond to bacterial antigens. J Immunol 1999; 162: 1884-8.
345. Cong Y, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998; 187: 855-64.
346. Iqbal N, Oliver JR, Wagner FH, et al. T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 2002; 195: 71-84.
347. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107: 1643-52.
348. Kitani A, Fuss IJ, Nakamura K, et al. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGFbeta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 2000; 192: 41-52.
349. Hahm KB, Im YH, Parks TWet al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001; 49: 190-8.
350. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF dependent Crohn's disease. Gastroenterology 2008; 134: 2025-35.
351. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1131-7.
352. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113: 383-9.
353. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory BowelDisease Cooperative Study Group. Gastroenterology 2000; 119: 1473-82.
354. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic activeCrohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119: 1461-72.